WallStSmart
VRCA

Verrica Pharmaceuticals Inc

NASDAQ: VRCA · HEALTHCARE · BIOTECHNOLOGY

$7.40
-1.79% today

Updated 2026-06-05

Market cap
$103.50M
P/E ratio
P/S ratio
2.79x
EPS (TTM)
$-1.10
Dividend yield
52W range
$3 – $10
Volume
0.1M

Verrica Pharmaceuticals Inc (VRCA) Financial statements

SEC filings — annual and quarterly data.

Profit margin
-50.27%
Operating margin
-33.56%
ROE
-111.03%
ROA
-20.90%
Debt/equity
0.09x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2016$0.00$-1.91M
2017$0.00$-4.46M
2018$0.00$-20.65M
2019$0.00$-27.95M
2020$12.00M$-45.50M-1.91%-334.84%-379.14%
2021$12.00M$-35.08M96.07%-257.57%-292.33%
2022$9.03M$-24.49M91.97%-235.78%-271.11%
2023$5.12M$-67.00M85.44%-1,283.35%-1,307.47%
2024$7.57M$-76.58M63.79%-871.25%-1,012.15%
2025$35.58M$-17.89M90.33%-33.56%-50.27%

Frequently asked questions

What is Verrica Pharmaceuticals Inc's revenue?

Verrica Pharmaceuticals Inc's trailing twelve-month revenue is $37.16M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is VRCA?

In its most recent fiscal year, VRCA ran a gross margin of 90.33%, an operating margin of -33.56%, and a net margin of -50.27%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does VRCA generate?

VRCA produced $-17.63M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is VRCA's balance sheet healthy?

VRCA holds $30.15M in cash and equivalents against — in long-term debt, on $24.74M of shareholder equity. That debt is best read against the cash flow the business throws off each year.